These findings suggested that GATM protein levels are associated with PBRM1 mutation status and less aggressive phenotypes and exhibit potential clinical utility as a prognostic marker for metastatic ccRCC with ICIs treatment. The gene discussed is GATM; the disease is nonpapillary renal cell carcinoma.